Health Care Value

Health Care Victories in the 2018 State Legislative Sessions

While congressional health care legislation stalled and federal actions undermined provisions of the Affordable Care Act, state policymakers stepped up to address a range of issues affecting health ca...

Risking Access to Needed Medicines for Medicaid Beneficiaries Will Not Fix High Drug Prices

Lowering the price of prescription drugs remains one of the top health care priorities for consumers.1 But pharmaceutical manufacturers continue to increase prices on lifesaving medications.2 A rece...

2018 State Legislation on High and Rising Drug Prices

2018 has been a year of opportunity when it comes to state legislation to address the high and rising prices of prescription drugs. Families USA has identified some of the 2018 state legislative sessi...

41 Consumer and Patient Groups Urge the Trump Administration to Take Real Action on Prescription Drugs

Families USA, Public Citizen, and 39 other national and state-based organizations including the Services Employees International Union, the National Partnership for Women and Families, the AFL-CIO, AF...

Families USA’s Comments on Proposed Rule on Medicare Part D Protected Classes

Late last year, the Trump administration released a proposed rule as part of its efforts to lower prescription drug prices that, if finalized, could have a significant impact on Medi...

Families USA Comments on Safe Harbor Rule

Families USA submitted this comment to Secretary Azar on the proposed safe harbor rule changes. Under the proposed rule, discounts awarded by prescription drug manufacturers to plan sponsors under M...

Letter to Congress: Strengthening Health Care and Lowering Prescription Drug Costs Act.

Families USA submitted the attached letter to U.S. House of Representatives Leadership in support of H.R. 987, the Strengthening Health Care and Lowering Prescription Drug Costs Act....

Frederick Isasi’s Testimony on High Drug Prices to the House Energy and Commerce Committee

In this testimony before the U.S. House of Representatives Energy and Commerce Committee on May 21, 2019, Frederick Isasi, Executive Director of Families USA, breaks down the problem with high drug ...

Medicare’s Drug Benefit: With Regulatory Action Off the Table, All Eyes Are on Capitol Hill

On May 16th, the Centers for Medicare and Medicaid Services announced a final regulation for Medicare’s Part D drug benefit for 2020. The regulation backed off of a proposal that would have crea...

Representative Doggett’s Medicare Negotiation Proposal to Meaningfully Lower Drug Prices

High and rising drug prices jeopardize consumers’ health and well-being.1 To address the harms of high drug prices, families across America want and deserve meaningful reforms that target and reduc...